Kwality PharmaceuticalsBOM:539997 -1.77%70 Piotroski F-Score is 6 as of Jul. 06, 2026, which is 14% below its 10-year median of 7.00. GuruFocus rates BOM:539997 with a GF Score™ of 70/100 and a GF Value™ of ₹1,158.95 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Kwality Pharmaceuticals ranks better than 79.2% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Kwality Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Kwality Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
BOM:539997'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 7 Max: 8
Current: 6
During the past 13 years, the highest Piotroski F-Score of Kwality Pharmaceuticals was 8. The lowest was 2. And the median was 7.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Kwality Pharmaceuticals Piotroski F-Score Related Terms
Kwality Pharmaceuticals Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Kwality Pharmaceuticals's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539997 vs ZTS, UTHR: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kwality Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kwality Pharmaceuticals Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kwality Pharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Kwality Pharmaceuticals's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Kwality Pharmaceuticals's current Net Income (TTM) was 673.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Kwality Pharmaceuticals's current Cash Flow from Operations (TTM) was 166.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Kwality Pharmaceuticals's return on assets of this year was 0.15057138. Kwality Pharmaceuticals's return on assets of last year was 0.1010759.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Kwality Pharmaceuticals's gearing of this year was 0.05656709. Kwality Pharmaceuticals's gearing of last year was 0.03593401.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Kwality Pharmaceuticals's current ratio of this year was 1.79885376. Kwality Pharmaceuticals's current ratio of last year was 1.67415415.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Kwality Pharmaceuticals's number of shares in issue this year was 10.377. Kwality Pharmaceuticals's number of shares in issue last year was 10.387.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Kwality Pharmaceuticals's gross margin of this year was 0.48629949. Kwality Pharmaceuticals's gross margin of last year was 0.50705597.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Kwality Pharmaceuticals's asset turnover of this year was 1.12478279. Kwality Pharmaceuticals's asset turnover of last year was 0.93908648.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
0
+
0
+
1
+
1
+
0
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Kwality Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Kwality Pharmaceuticals (BOM:539997) has a Piotroski F-Score of 6 as of Jul. 06, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Kwality Pharmaceuticals and its competitors. This is 14% below median its historical median of 7.00. Over the past decade, Kwality Pharmaceuticals' Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Kwality Pharmaceuticals ranks #204 out of 981 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Kwality Pharmaceuticals' Piotroski F-Score too high?
Kwality Pharmaceuticals' current Piotroski F-Score of 6 is 14% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Kwality Pharmaceuticals' value of 6 is 20% above this industry median. Based on the distribution chart, Kwality Pharmaceuticals ranks #204 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kwality Pharmaceuticals has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kwality Pharmaceuticals' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kwality Pharmaceuticals ranks #204 out of 981 companies for Piotroski F-Score. This places Kwality Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Kwality Pharmaceuticals' value of 6 is 20% above this benchmark. Historically, Kwality Pharmaceuticals' own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Kwality Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kwality Pharmaceuticals's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Kwality Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kwality Pharmaceuticals's current Piotroski F-Score is 6, which is 14% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kwality Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Kwality Pharmaceuticals (BOM:539997) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,158.95, compared to a current price of ₹2,676.00 — trading 130.9% above its estimated fair value. The current Piotroski F-Score is 6, which is 14% below median its 10-year median of 7.00 and 20% above the Drug Manufacturers industry median of 5.00. Kwality Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Kwality Pharmaceuticals (BOM:539997), the current Piotroski F-Score is 6 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kwality Pharmaceuticals (BOM:539997) Overvalued in 2026?
Based on GuruFocus' analysis, Kwality Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,676.00 is trading 130.9% above its estimated GF Value™ of ₹1,158.95.
GuruFocus considers Kwality Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:539997:
Piotroski F-Score: 6 (14% below median its 10-year median of 7.00)
GF Value™: ₹1,158.95 vs. price of ₹2,676.00 (130.9% above fair value)
Industry Position: 20% above the Drug Manufacturers median (#204 of 981)
No single metric tells the full story. See the BOM:539997 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kwality Pharmaceuticals Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing finished pharmaceutical formulations in a dosage form. The company manufactures and exports pharmaceutical formulations in liquid orals, dry syrups, tablets, capsules, sterile powder for injections, and small-volume injectables.
70GF Score
Get the complete analysis for BOM:539997
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539997 has been successfully added to your 
